根據 位華爾街分析師的預測,ACRO Biomedical Co Ltd 的收入預期範圍從 $ 到 $
ACRO Biomedical Co Ltd 的盈利品質評分是多少?
ACRO Biomedical Co Ltd 的盈利品質評分為 A-/58.619442。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
ACRO Biomedical Co Ltd 何時發布財報?
ACRO Biomedical Co Ltd 的下一份財報預計在 2026-05-12 發布
ACRO Biomedical Co Ltd 的預期收益是多少?
根據華爾街分析師的預測,ACRO Biomedical Co Ltd 的預期收益為 $
ACRO Biomedical Co Ltd 是否超出收益預期?
ACRO Biomedical Co Ltd 最近的收益為 $, 預期。
關鍵數據
前收市價
$0.026
開盤價
$0.026
當日範圍
$0.026 - $0.026
52週區間
$0.0007 - $0.036
交易量
66
平均成交量
55
股息收益率
--
每股盈餘 (TTM)
-0.00
市值
$1.5M
什麼是 ACBM?
Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.